In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 147 for your search:

Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Treatment/Intervention:  neoadjuvant therapy
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging

Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LITE Randomized Pilot Study, NCT00531973

Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: BCP06, NCT01199432

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P0334, NCT01501487

An Open-label, Multi-center Phase ? Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer

Phase: Phase IV
Type: Treatment
Status: Active
Age: 20 to 70
Sponsor: Other
Protocol IDs: 4-2011-0068, NCT01660542

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WHC-MRI-GU-2006-097, NCT00397761

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 0120070323, NCT00698971

Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: M09TNM, 2009-015238-31, NCT01057069

The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 30 to 70
Sponsor: Other
Protocol IDs: MVH-03, 2010-022460-12, 2007-58-0015/HEH.750.89-12, H-4-2011-007, NCT01355523

Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: DLBS1425-0310, NCT01433562

10.

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: aesa, NCT01647672

11.

Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: TENBC, NCT01648608

12.

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GBG-GEPARQUATTRO, GBG-40, EU-205101, AVENTIS-GBG-GEPARQUATTRO, ROCHE-AVENTIS-GBG-GEPARQUATTRO, EUDRACT-2005-001546-17, NCT00288002

13.

Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CRUK-OPTION, EUDRACT-2004-000133-11, CRUK-BR0402, ISRCTN84856516, EU-20680, NCT00427245

14.

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WMS-PERSEPHONE, MREC-PERSEPHONE, PERSEPHONE, EUDRACT: 2006-007018-39, ISRCTN 52968807, MREC 07/MRE08/35, PERSEPHONE, EU-20858, CRUK-BRD/07/137, NCT00712140

15.

Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 20
Sponsor: Other
Protocol IDs: 200803006M, NCT00776724

16.

Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: DBCG 07-REAL, NCT00908531

17.

Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: NATT, NCT00912444

18.

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRCA-CCTC-WCTU-ARTemis, CCTC-WCTU-ARTemis, ISRCTN68502941, EUDRACT-2008-002322-11, EU-21017, MREC-08/H1102/104, NCT01093235

19.

Doxorubicin Hydrochloride, Cyclophosphamide, and Docetaxel With or Without Zoledronic Acid in Treating Patients With Large Resectable or Locally Advanced Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BOOG-2010-01, BOOG-2010-01-NEO-ZOTAC, BOOG-NEO-ZOTAC, EUDRACT-2009-016932-11, EU-21023, NCT01099436

20.

Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000669882, ICR-CTSU-2008-10017, UM-EPHOS-B, CRUK-08-002, MREC-09-H1208-52, ISRCTN-15004993, EUDRACT-2008-005466-30, EU-21029, GSK-ICR-CTSU-2008-10017, UM-CR-CTSU/2008/10017,EPHOS-B, NCT01104571

21.

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 102-00-301, NCT01204801

22.

Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BOOG 2010-05, NCT01392586

23.

Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Endostar B-02, CBCRT01, NCT01479036

24.

Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 69, 2011-004714-41, NCT01583426

25.

Neo-Adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer